GnRH Agonist as Luteal Support in FET Cycles
Phase 4
Completed
- Conditions
- Infertility
- Interventions
- Drug: Hormone replacement cycle and triptorelin acetate 0.1 mg
- Registration Number
- NCT02620124
- Lead Sponsor
- Turku University Hospital
- Brief Summary
Back ground: A single dose of GnRH analogue in the luteal phase is reported to improve the outcome of IVF/ICSI treatments but the effect in FET cycles has not been reported.
Aim: To compare the results of frozen thawed embryo transfers with and without GnRHa analogue support Primary end point: IR, PR, on going PR Secondary end point: hCH, E2 and progesterone levels 14 days after thawing
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- 20 - 45 year old women comig to frozen thawed embryo transfer
Exclusion Criteria
- The age of the woman over 42 years during the initial ICF/ICSI- treatment from which the embryos derive
- Abnormal uterus
- Known abnormality of karyotype of the woman or her partner
- Severe male factor as an exclusive reason for subfertility
- Allegy for triptorelin acetate
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Hormone replacement cycle, intervention Hormone replacement cycle and triptorelin acetate 0.1 mg Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
- Primary Outcome Measures
Name Time Method Implantation rate five weeks after the embryo transfer Pregnancy rate five weeks after the embryo transfer Ongoing pregnancy rate ten weeks after the embryo transfer
- Secondary Outcome Measures
Name Time Method hCG- level 14 days after thawing of the embryos